Furui Co.,Ltd(SZ:300049)2022-12-08 01:31Financial Performance - The company achieved a profit of over 45 million in the first three quarters, with a non-deductible profit of over 47 million [2] - The majority of domestic profits are contributed by pharmaceuticals, particularly from the "Love Liver" management center [2] International Sales - In 2014, approximately 100 units of Fibroscan were sold in the U.S., with around 90 units sold in 2015 so far, indicating significant growth [2] - The Fibroscan device is currently sold directly in Western Europe and China, with plans to start direct sales in the U.S. next year [3] Product Pricing and Competition - The cost for a single Fibroscan test ranges from 120 to 180 yuan [3] - There are currently no competitors for Fibroscan in the global market [3] Fibroscan Model and Production - The main model sold is Fibroscan 502, with the older model 402 being less common in the market [3] - Fibroscan's lifespan is rated at 8 years, and calibration is required after 6 months or 2000 tests, costing approximately 30,000 yuan in China [4] Love Liver Management Center - There are over 90 "Love Liver" management centers, which are in the process of expanding profitability [4] - The center has over 40,000 online members and approximately 100,000 offline members [4] Drug Portfolio - The company represents over 80 types of drugs, primarily antiviral and liver protection medications [4] Future Strategies - The company is preparing to establish a medical device company in Shenzhen for the production, research, and sales of Fibroscan in China [3] - Future acquisitions will focus on liver disease diagnostics and treatments, with both domestic and international options being considered [5]